Toggle Main Menu Toggle Search

Open Access padlockePrints

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

Lookup NU author(s): Professor Chris Day, Julian Leathart, Professor Ann Daly

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The mechanism by which diclofenac-induced hepatotoxicity occurs is unclear, even though covalent modification of proteins by diclofenac metabolites appears to be important in pathogenesis, either by altering protein function or by eliciting an immune response. Adduct formation may be due to metabolism of diclofenac via an alternative pathway rather than via its major 4'-hydroxylation pathway mediated by the cytochrome P450 CYP2C9. We hypothesized that possession of variant CYP2C9 alleles might be a risk factor for diclofenac-induced hepatotoxicity, since the allelic variants CYP2C9*2 and CYP2C9*3 may be associated with impaired metabolism compared to the wild-type (CYP2C9*1). To investigate in more detail the effects of the polymorphisms on diclofenac metabolism in human liver, the kinetics of diclofenac 4-hydroxylation by human liver microsomes of known CYP2C9 >genotype were examined. An overall difference in V(max) and V(max)/K(m) between samples homozygous for CYP2C9*1 and heterozygous for CYP2C9*2 or CYP2C9*3 was detected (P = 0.044). However, on subgroup analysis, there was no significant difference between samples homozygous for CYP2C9*1 and heterozygous for CYP2C9*2, although there was a borderline difference between the samples homozygous for CYP2C9*1 and those heterozygous for CYP2C9*3 (P = 0.057). The relationship between CYP2C9 genotype and susceptibility to diclofenac-induced hepatotoxicity was further examined by genotyping 24 patients with diclofenac-induced hepatotoxicity together with 100 healthy controls for the CYP2C9*2 and CYP2C9*3 alleles. CYP2C9 genotype frequencies for CYP2C9*2 and CYP2C9*3 were similar in patients and controls. To assess whether diclofenac-induced hepatotoxicity was due to rare CYP2C9 mutations, the upstream sequence (-1 to -1000) and all exons and exon-intron boundaries of CYP2C9 from four subjects who had suffered severe hepatotoxicity was determined. However, no new polymorphisms were detected. We therefore found no evidence that polymorphism in CYP2C9 is a determinant of diclofenac-induced hepatotoxicity. (C) 2000 Lippincott Williams and Wilkins.


Publication metadata

Author(s): Leathart JBS; Daly AK; Day CP; Aithal GP

Publication type: Article

Publication status: Published

Journal: Pharmacogenetics

Year: 2000

Volume: 10

Issue: 6

Pages: 511-518

ISSN (print): 0960-314X

ISSN (electronic):

Publisher: Lippincott Williams & Wilkins

URL: http://dx.doi.org/10.1097/00008571-200008000-00004

DOI: 10.1097/00008571-200008000-00004

PubMed id: 10975605


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share